Tracers / [111In]AT2S

[111In]AT2S

Also written as [In-111]In-AT2S

Radionuclide: In-111 t½ 4031.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated somatostatin-14 (SST-14) analog radioligand
Target / mechanism: Binds with high affinity to all five somatostatin receptor subtypes (SST1-5R) PMID 38543286
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>95%	>95%	AT2S In-house / non-commercial (various)	38543286 2024 Pharmaceutics The radiolabeling with [111In]InCl3 was conducted in low protein binding Eppendorf tubes. — The radiopeptides were obtained in >95% radiochemical yields

Need this precursor?We can point you to suppliers for [111In]AT2S, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38543286. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.